Genovis AB logo

Genovis AB (5GV)

Market Open
11 Aug, 20:00
XFRA XFRA
1. 74
-0.01
-0.4587%
117.46M Market Cap
60.24 P/E Ratio
- Div Yield
300 Volume
1.41 Eps
1.74
Previous Close
Add Transaction
Day Range
1.74 1.74
Year Range
1.41 2.38
Want to track 5GV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

5GV trading today lower at €1.74, a decrease of -0.4587% from yesterday's close, completing a monthly increase of 1.1655% or €0.02. Over the past 12 months, 5GV stock lost -8.8235%.
5GV is not paying dividends to its shareholders.
The last earnings report, released on May 19, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

5GV Chart

People also search for

722
Antengene Corporation Limited
0.48
-5.7426%
7W3
Acotec Scientific Holdings Limited
0.81
-2.994%
Flerie AB (publ)
1.73
-10.6218%
R9Z
Immuneonco Biopharmaceutical Inc.
0.38
+2.7174%
25E
Elan Corporation plc
4.02
+3.0769%

Genovis AB (5GV) FAQ

What is the stock price today?

The current price is €1.74.

On which exchange is it traded?

Genovis AB is listed on XFRA.

What is its stock symbol?

The ticker symbol is 5GV.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 117.46M.

Has Genovis AB ever had a stock split?

No, there has never been a stock split.

Genovis AB Profile

Biotechnology Industry
Healthcare Sector
Mr. Fredrik Olsson CEO
XFRA Exchange
SE0002485979 ISIN
SE Country
42 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Founded in 1999 and based in Lund, Sweden, Genovis AB (publ.) is at the forefront of developing innovative tools aimed at revolutionizing treatment methods and diagnostics within the pharmaceutical and medical device industries. The company's commitment to advancing healthcare is evident in its broad range of products designed to cater to various aspects of pharmaceutical and biotechnological research and development. By serving a diverse clientele that spans across pharmaceutical and biotech companies, contract research organizations, and contract manufacturing companies, Genovis AB underscores its global footprint not just in its native Sweden, but across Europe, North America, and Asia. Through its dedicated online store, the company ensures that its groundbreaking products are easily accessible to its worldwide customer base.

Products and Services

  • FabALACTICA: A cysteine protease specifically designed to digest human IgG1 antibodies.
  • FabRICATOR: Known for its ability to digest the hinge region of IgG antibodies, allowing for the separation of these molecules into distinct fragments.
  • FabRICATOR Z: Tailored for the digestion of mouse IgG2a and IgG3 antibodies, it facilitates the generation of a homogenous pool of F(ab')2 and Fc fragments.
  • FabULOUS (SpeB): An enzyme targeting the digestion of IgG in the hinge region to create consistent and predictable antibody fragments.
  • GingisKHAN: Another cysteine protease, but specifically engineered for the effective digestion of human IgG1.
  • FabDELLO: Focuses on the precise digestion of human IgG1 to aid in detailed structural and functional antibody studies.
  • GingisREX: A cysteine protease renowned for its specificity in digesting peptide bonds C-terminally to the specified sites.
  • GlySERIAS: Developed to cleave flexible glycine-rich fusion protein linkers, streamlining the purification or modification processes.
  • GlyCLICK: Represents a conjugation technology engineered for site-specific and quantitative IgG conjugation, enhancing the precision of antibody-drug conjugates.
  • TransGLYCIT: A platform technology enabling site-specific remodeling of human IgG glycans, crucial for adjusting effector functions or improving stability.
  • OmniGLYZOR: Offers a combination of immobilized enzymes for broad application in glycan remodeling or analysis.
  • PNGase F: A glycoamidase that hydrolyzes the amide bond between the polypeptide asparagine and the innermost GlcNAc, essential for N-glycan analysis.
  • OpeRATOR: Specialized as an O-glycan-specific protease, it aids in the detailed analysis and modification of glycoproteins.
  • OglyZOR: Acts as an endoglycosidase for the removal of O-linked glycans, facilitating studies on protein structure and function.
  • SialEXO, FucosEXO, GalactEXO, GalNAcEXO: A suite of enzymes designed for the specific removal of sialic acids, fucoses, galactoses, and N-acetylgalactosamines, respectively, aiding in the precise modification and analysis of glycoproteins and glycopeptides.
  • GlycOCATCH: An affinity resin that enables the purification of mucin-type O-glycosylated proteins and peptides, important for studies on mucin-like glycoproteins.
  • GlycINATOR (EndoS2) & IgGZERO (EndoS): Both are IgG-specific endoglycosidases, with the former being specific for certain glycoforms, crucial in the modulation of antibody effector functions.
  • Anti-FabRICATOR (Anti-IdeS) & Anti-FabRICATOR Z (Anti-IdeZ): Comprise goat polyclonal antibodies against the respective enzymes, useful in immunoassays and enzyme inhibition studies.

Contact Information

Address: Box 4, Kävlinge, Sweden, 244 21
Phone: 46 46 10 12 30